Vancomycin resistant enterococcus faecium infections - pipeline review, q3 2011

Uploaded on

This report provides information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and …

This report provides information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, Q3 2011SummaryGlobal Markets Direct’s Vancomycin-Resistant Enterococcus Faecium Infections - PipelineReview, Q3 2011 provides an overview of the Vancomycin-Resistant Enterococcus FaeciumInfections therapeutic pipeline. This report provides information on the therapeuticdevelopment for Vancomycin-Resistant Enterococcus Faecium Infections, complete withlatest updates, and special features on late-stage and discontinued projects. It also reviewskey players involved in the therapeutic development for Vancomycin-Resistant EnterococcusFaecium Infections. Vancomycin-Resistant Enterococcus Faecium Infections - PipelineReview, Q3 2011 is built using data and information sourced from Global Markets Direct’sproprietary databases, Company/University websites, SEC filings, investor presentationsand featured press releases from company/university sites and industry-specific third partysources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on the availabilityand relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Vancomycin-Resistant EnterococcusFaecium Infections.- A review of the Vancomycin-Resistant Enterococcus Faecium Infections products underdevelopment by companies and universities/research institutes based on informationderived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery tillregistration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on thebasis of therapeutic class, route of administration and molecule type.- Profiles of late-stage pipeline products featuring sections on product description,mechanism of action and research & development progress.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Browse All Pharmaceuticals Market Research ReportsReasons to buy- Identify and understand important and diverse types of therapeutics under developmentfor Vancomycin-Resistant Enterococcus Faecium Infections.- Identify emerging players with potentially strong product portfolio and design effectivecounter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players with the most promisingpipeline.- Devise corrective measures for pipeline projects by understanding Vancomycin-ResistantEnterococcus Faecium Infections pipeline depth and focus of Vancomycin-ResistantEnterococcus Faecium Infections therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective
  • 2. partners with the most attractive projects to enhance and expand business potential andscope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding thefactors that drove them from pipeline.Table of ContentsTable of Contents 2List of Tables 4List of Figures 5Introduction 6Global Markets Direct Report Coverage 6Vancomycin-Resistant Enterococcus Faecium Infections Overview 7Therapeutics Development 8An Overview of Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections8Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics under Development byCompanies 10Late Stage Products 12Comparative Analysis 12Early Clinical Stage Products 13Comparative Analysis 13Discovery and Pre-Clinical Stage Products 14Comparative Analysis 14Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Products underDevelopment by Companies 15Companies Involved in Vancomycin-Resistant Enterococcus Faecium Infections TherapeuticsDevelopment 16Achillion Pharmaceuticals, Inc. 16Paratek Pharmaceuticals, Inc. 16Immtech Pharmaceuticals, Inc. 17Lorus Therapeutics Inc 17Oragenics, Inc. 18Piramal Life Sciences Limited 18MerLion Pharmaceuticals Pte Ltd 19MicuRx Pharmaceuticals, Inc. 19Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics Assessment 20Assessment by Monotherapy Products 20Assessment by Route of Administration 21Assessment by Molecule Type 23Drug Profiles 25ACH-702 - Drug Profile 25Product Description 25Mechanism of Action 25R&D Progress 25LOR-220 - Drug Profile 26Product Description 26Mechanism of Action 26R&D Progress 26Omadacycline - Drug Profile 27Product Description 27Mechanism of Action 27
  • 3. R&D Progress 27Drug for Bacterial Infections - Drug Profile 29Product Description 29Mechanism of Action 29R&D Progress 29MU1140 - Drug Profile 30Product Description 30Mechanism of Action 30R&D Progress 30Lipopetide Program - Drug Profile 31Product Description 31Mechanism of Action 31R&D Progress 31PM181104 - Drug Profile 32Product Description 32Mechanism of Action 32R&D Progress 32Lipopeptide Program - Drug Profile 33Product Description 33Mechanism of Action 33R&D Progress 33MRX-I - Drug Profile 34Product Description 34Mechanism of Action 34R&D Progress 34MRX-II - Drug Profile 35Product Description 35Mechanism of Action 35R&D Progress 35SLP0905 - Drug Profile 36Product Description 36Mechanism of Action 36R&D Progress 36SLP0904 - Drug Profile 38Product Description 38Mechanism of Action 38R&D Progress 38Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics – Drug Profile Updates40Vancomycin-Resistant Enterococcus Faecium Infections - Featured News 41Oct 21, 2010: Lorus Therapeutics Announces Allowance Of US Patent For Lead AntimicrobialSmall Molecule 41Appendix 42Methodology 42Coverage 42Secondary Research 42Primary Research 42Expert Panel Validation 43Contact Us 43Disclaimer 43
  • 4. About Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: Facebook Page Rambler road,Suite727,Dallas,TX75231Tel: +1-888-989-8004E-mail: sales@reportsandreports.comhttp://www.reportsandreports.comVisit our Market Research Blog